L'Oreal is making human skin in the lab to test products and reduce animal testing. Coming soon: 3-D printed skin for tissue engineering. » Read More
CNBC's Meg Tirrell reports on the biggest health issues and how industry leaders are thinking about the future of health care in America. David Gluckman, Lazard co-head of health care, weighs in. » Read More
By: Alexandra Ossola
Over the course of a year, scientists sampled the microbes in a newly-opened facility in Chicago, Vocativ reports. » Read More
CNBC's Meg Tirrell reports on Puma's stock spike after the FDA board votes in support of its breast cancer drug. » Read More
Leerink says Sarepta Therapeutics will generate $89 million in 2017 sales vs. management's guidance of more than $80 million.
Amicus Therapeutics CEO Crowley is optimistic about Trump's plans to work with the pharma industry, proposing change for good.
The stock slid sharply in morning trading before rebounding to climb about 1 percent higher Wednesday.
Shares of EpiPen maker Mylan climbed on the heels of the company reporting fourth-quarter earnings that topped expectations.
The hire signals Carl Icahn may be back, at a time when biotech valuations are 25 percent off their 2015 highs.
CNBC's Meg Tirrell and Arie Belldegrun, CEO of Kite Pharmaceuticals, discuss what's behind the company's big stock day.
CNBC's Meg Tirrell looks at Perrigo and Valeant, two biotech names moving lower today.
Johnson & Johnson said the net increase in the cost of its medicines across its portfolio was 3.5 percent.
The World Health Organization creates the list to spur research for new antibiotics that can counter increasingly resistant bacteria.
Shares of Incyte rose more than 6 percent in Friday trade on news that the pharmaceutical company will join the S&P 500.
The death rate from drug overdoses more than doubled between 1999 and 2015, according to a report from the CDC.
CNBC's Ylan Mui discusses how the Trump administration's planned overhaul of the tax code could impact inversion deals and drug companies.
David Ricks, Eli Lilly CEO, weighs in on tax reform priorities, border adjustment tax and drug pricing.
“We price our drugs in line with their innovation potential and in line with the competitive environment,” Werner Baumann, CEO of Bayer, told CNBC.
Arix Bioscience CEO Dr Joe Anderson discusses investment in biotechnology, adding that academic science is the focus of innovation in the industry.
Shares of Bristol-Myers climbed as much as 4 percent after billionaire Carl Icahn reportedly took a stake in the company, according to Dow Jones.
Shkreli is accused of ripping off his former pharma company Retrophin to pay off hedge-fund investors he was accused of defrauding.
Momenta says Pfizer, a key supplier for its multiple sclerosis drug, has received a warning letter from the Food and Drug Administration.
Recursion Pharmaceuticals is using robots to find treatments for rare diseases like sickle cell anemia and cystic fibrosis.
While the development of contraceptives aimed at men is gaining ground, interest from big pharma just isn't there, according to one expert.
Get the best of CNBC in your inbox